Cytospire Therapeutics raises £61M in Series A funding to advance innovative cancer immunotherapy targeting gamma delta T ...
Cytospire Therapeutics was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...
SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel ...
The Brighterside of News on MSN
Study finds low-dose CAR T therapy can drive complete cancer remission
A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For ...
There are differences between familial and idiopathic pulmonary fibrosis in terms of cluster of differentiation 20 and CD3 expression.
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results